Figure 5
Figure 5. RvE1 stereoselectively blocks ADP-stimulated platelet aggregation in PRP. (A left) Percentage inhibition ADP (10 μM)–induced platelet aggregation. (A right) PRP from aspirinated healthy donors was incubated with RvE1 or protectin D1, PD1 (15 minutes, 37°C); see inset. (B,C) Direct comparison of RvE1 (100 nM) and Δ6,14-trans-RvE1 (100 nM). Results are percentage inhibition of ADP-stimulated PRP; means plus or minus SEM from 3 to 6 experiments with different PRP preparations. *P < .05; ***P < .001.

RvE1 stereoselectively blocks ADP-stimulated platelet aggregation in PRP. (A left) Percentage inhibition ADP (10 μM)–induced platelet aggregation. (A right) PRP from aspirinated healthy donors was incubated with RvE1 or protectin D1, PD1 (15 minutes, 37°C); see inset. (B,C) Direct comparison of RvE1 (100 nM) and Δ6,14-trans-RvE1 (100 nM). Results are percentage inhibition of ADP-stimulated PRP; means plus or minus SEM from 3 to 6 experiments with different PRP preparations. *P < .05; ***P < .001.

Close Modal

or Create an Account

Close Modal
Close Modal